Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

BACKGROUND: The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3(rd )or later-...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lièvre, Astrid, Samalin, Emmanuelle, Mitry, Emmanuel, Assenat, Eric, Boyer-Gestin, Christine, Lepère, Céline, Bachet, Jean-Baptiste, Portales, Fabienne, Vaillant, Jean-Nicolas, Ychou, Marc, Rougier, Philippe
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2009
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2761407/
https://ncbi.nlm.nih.gov/pubmed/19785749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-347
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky